Leflunomide and the lung

Rheumatology

Volumn 48, Issue 9, 2009, Pages 1017-1018

  Kelly, Clive ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE;

AGE DISTRIBUTION; BODY MASS; CAUCASIAN; COMPARATIVE STUDY; DRUG CONTRAINDICATION; DRUG USE; EDITORIAL; GENETIC ANALYSIS; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPAN; KOREA; LUNG INJURY; MEDICAL PRACTICE; MORTALITY; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX RATIO; SMOKING; CHEMICALLY INDUCED DISORDER; LUNG DISEASE; NOTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; ISOXAZOLES; LUNG DISEASES;

EID: 70349785866     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep164     Document Type: Editorial

References (15)

1. Kalden JR, Schattenkirchner M, Sorensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five year follow up study. Arthritis Rheum 2003;48:1513-20.
2. Ito S, Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004;43:1103-4.
3. Kamata Y, Nara H, Kamimura T et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201-4.
4. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363:461.
5. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005;32:1160-3.
6. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med 2006;45:689-91.
7. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9.
8. Sawada T, Inokuma S, Sato T et al. Leflunomide induced interstitial lung disease; prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009;48:1069-72.
9. Chikura B, Lane S, Dawson J. Clinical expression of leflunomide induced pneumonitis. Rheumatology 2009;48:1065-8.
10. Ju JH, Kim SI, Lee JH et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007;56:2094-6.
11. Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006;36:162-9.
12. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007;34:1934-7.
13. Howes M, Tose J, White C, Kumar N, Heycock C, Kelly C. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis. Intern Med 1999;7:51-4.
14. Rajasekaran BA, Shovlin D, Saravanan V, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis; a comparison with cryptogenic fibrosing alveolitis over five years. J Rheumatol 2006;33:1250-4.
15. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 2004;43:143-7.